A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, REPEAT DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF OLIPUDASE ALFA IN PATIENTS WITH ACID SPHINGOMYELINASE DEFICIENCY
- Registry ID
- DFI12712
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Last update
- 2020-10-21
Conditions
- ACID SPHINGOMYELINASE DEFICIENCY
View on source registry